The Business Research Company’s report on the Gestational Diabetes Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the gestational diabetes industry?
The increasing obese population is expected to propel the growth of the gestational diabetes market going forward. The obese population is individuals whose body mass index (BMI) is 30 or higher, indicating excessive body fat that may pose significant health risks. The obese population is rising due to a combination of sedentary lifestyles, increased consumption of high-calorie, processed foods, genetic predispositions, and limited access to healthy food and exercise options. Gestational diabetes treatment is crucial for the obese population because their higher risk of insulin resistance and excessive weight gain during pregnancy can lead to complications for both mother and baby if left unmanaged. For instance, in March 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 1 in 8 people globally were living with obesity in 2022, with 2.5 billion adults aged 18 and older classified as overweight, including 890 million individuals living with obesity. Among adults, 43% were overweight, and 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight, while over 390 million children and adolescents aged 5–19 years were overweight, including 160 million living with obesity. Therefore, the increasing obese population is driving the gestational diabetes market.
Access Your Free Sample of the Global Gestational Diabetes Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20818&type=smp
What is the estimated market size of the gestational diabetes sector by 2029, based on current forecasts?
The gestational diabetes market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increase the risk of diabetes, increased as accuracy in measuring blood glucose levels, increased number of the insurance players, increase in the population of diabetic patients, growing diabetes population.
The gestational diabetes market size is expected to see strong growth in the next few years. It will grow to $12.90 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increase in rate of obesity, growing acceptance of cloud-based project arrangements and the expanding use of related devices and apps, increasing prevalence of diabetes due to unhealthy lifestyles among people, increase in public health consciousness, rising prevalence rates of diabetes. Major trends in the forecast period include digital diabetes management apps, closed-loop control systems, diabetes management technology, enzymatic technology, innovative medical technologies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20818&type=smp
#Who are the top players in the gestational diabetes market?
Major companies operating in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc
#What are the major trends in the gestational diabetes market?
Major companies operating in the gestational diabetes market are focusing on developing technologically advanced products, such as diagnostic kits for gestational diabetes, to provide quick, accurate, and convenient methods for early detection. A diagnostic kit for gestational diabetes is a medical tool used to measure blood glucose levels and identify abnormal glucose tolerance in pregnant women, aiding in the early detection and management of the condition. For instance, in August 2024, DirectSens GmbH, an Austria-based biotechnology company, launched the XpressGT RUO kit, a diagnostic kit designed to diagnose gestational diabetes, endometriosis, insulin resistance, and liver disease. It accurately measures 2-hydroxybutyrate (2-HB) levels found in venous blood, naturally produced by the liver during its normal functions. Elevated 2-HB levels are associated with increased reductive stress, linked to various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any available clinical analyzer and delivers results in just 8 minutes, offering a fast and efficient diagnostic solution.
Which geography holds the highest gestational diabetes market share?
North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/gestational-diabetes-global-market-report
How do different segments contribute to the overall expansion of the gestational diabetes market?
The gestational diabetes market covered in this report is segmented –
1) By Types: Type A1, Type A2, Other Types
2) By Treatment: Monitoring, Drug Treatment, Non-pharmacological treatment
3) By Administration: Oral, Intravenous, Other Administrations
4) By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Centers
Subsegments:
1) By Type A1: Diet-Controlled Gestational Diabetes, Exercise-Controlled Gestational Diabetes
2) By Type A2: Insulin-Controlled Gestational Diabetes, Oral Medication-Controlled Gestational Diabetes
3) By Other Types: Pre-Gestational Diabetes, Gestational Diabetes With Complications
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20818
How is the gestational diabetes market defined, and what are its core characteristics?
Gestational diabetes is a type of diabetes that develops during pregnancy when the body cannot produce enough insulin to regulate blood sugar levels effectively. This condition typically occurs in the second or third trimester and can affect women who have no prior history of diabetes. Gestational diabetes poses risks to both the mother and baby, including high birth weight, preterm birth, and potential development of type 2 diabetes later in life for both. It is often managed through dietary adjustments, exercise, blood sugar monitoring, and sometimes insulin therapy to ensure a healthy pregnancy and delivery.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
